Acurx Pharmaceuticals CEO David Luci tells Soulstring Media Group why he thinks his company and lead drug candidate, Ibezapolstat, can be a front-line treatment against C. difficile New York, New York (Newsfile
The Clostridium difficile infection market is anticipated to surge owing to the launch of emerging therapies. The potential emerging treatment expected to launch in the forecast period includes
– Summarized data from the study s secondary endpoints show investigational oral microbiome therapeutic rapidly and durably lowered risk of recurrent C. difficile infection – . | October 19, 2022
Il terzo gol ufficiale con la maglia della Juventus, oltre a quello cancellato contro la Salernitana, certifica l ottimo impatto avuto da Arkadiusz Milik nel .
New research published in the Frontiers in Pediatrics on pediatric patients with clostridium difficile infections (CDI) could ultimately result in future studies identifying risk factors within the.
NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) said Tuesday that the CLOVER trial, a pivotal Phase 3 study evaluating its Clostridioides difficile vaccine candidate (PF-06425090) in the prevention
Pfizer Inc. on Tuesday reported mixed results from a Phase 3 study of PF-06425090, its vaccine candidate for the prevention of C. difficile infection, or CDI.